Switch theme
Sign up to access all valuation multiples
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
2005
5
LTM Revenue $5.5M
LTM EBITDA -$11.0M
$49.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abionyx Pharma has a last 12-month revenue (LTM) of $5.5M and a last 12-month EBITDA of -$11.0M.
In the most recent fiscal year, Abionyx Pharma achieved revenue of $5.3M and an EBITDA of -$4.9M.
Abionyx Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abionyx Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.5M | XXX | $5.3M | XXX | XXX | XXX |
| Gross Profit | $1.1M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA | -$11.0M | XXX | -$4.9M | XXX | XXX | XXX |
| EBITDA Margin | -199% | XXX | -92% | XXX | XXX | XXX |
| EBIT | -$11.3M | XXX | -$5.1M | XXX | XXX | XXX |
| EBIT Margin | -204% | XXX | -95% | XXX | XXX | XXX |
| Net Profit | -$9.8M | XXX | -$5.1M | XXX | XXX | XXX |
| Net Margin | -177% | XXX | -96% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Abionyx Pharma's stock price is EUR 1 (or $1).
Abionyx Pharma has current market cap of EUR 42.5M (or $49.9M), and EV of EUR 42.1M (or $49.3M).
See Abionyx Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $49.3M | $49.9M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Abionyx Pharma has market cap of $49.9M and EV of $49.3M.
Abionyx Pharma's trades at 9.2x EV/Revenue multiple, and -10.0x EV/EBITDA.
Equity research analysts estimate Abionyx Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abionyx Pharma has a P/E ratio of -5.1x.
See valuation multiples for Abionyx Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $49.9M | XXX | $49.9M | XXX | XXX | XXX |
| EV (current) | $49.3M | XXX | $49.3M | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | -4.5x | XXX | -10.0x | XXX | XXX | XXX |
| EV/EBIT | -4.4x | XXX | -9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 46.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.1x | XXX | -9.7x | XXX | XXX | XXX |
| EV/FCF | -5.9x | XXX | -11.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbionyx Pharma's last 12 month revenue growth is 22%
Abionyx Pharma's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.2M for the same period.
Abionyx Pharma's rule of 40 is -50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abionyx Pharma's rule of X is -145% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Abionyx Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | -199% | XXX | -92% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -50% | XXX | -71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -145% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 114% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abionyx Pharma acquired XXX companies to date.
Last acquisition by Abionyx Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Abionyx Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Abionyx Pharma founded? | Abionyx Pharma was founded in 2005. |
| Where is Abionyx Pharma headquartered? | Abionyx Pharma is headquartered in France. |
| How many employees does Abionyx Pharma have? | As of today, Abionyx Pharma has 5 employees. |
| Is Abionyx Pharma publicy listed? | Yes, Abionyx Pharma is a public company listed on PAR. |
| What is the stock symbol of Abionyx Pharma? | Abionyx Pharma trades under ABNX ticker. |
| When did Abionyx Pharma go public? | Abionyx Pharma went public in 2015. |
| Who are competitors of Abionyx Pharma? | Similar companies to Abionyx Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Abionyx Pharma? | Abionyx Pharma's current market cap is $49.9M |
| What is the current revenue of Abionyx Pharma? | Abionyx Pharma's last 12 months revenue is $5.5M. |
| What is the current revenue growth of Abionyx Pharma? | Abionyx Pharma revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Abionyx Pharma? | Current revenue multiple of Abionyx Pharma is 8.9x. |
| Is Abionyx Pharma profitable? | Yes, Abionyx Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Abionyx Pharma? | Abionyx Pharma's last 12 months EBITDA is -$11.0M. |
| What is Abionyx Pharma's EBITDA margin? | Abionyx Pharma's last 12 months EBITDA margin is -199%. |
| What is the current EV/EBITDA multiple of Abionyx Pharma? | Current EBITDA multiple of Abionyx Pharma is -4.5x. |
| What is the current FCF of Abionyx Pharma? | Abionyx Pharma's last 12 months FCF is -$8.3M. |
| What is Abionyx Pharma's FCF margin? | Abionyx Pharma's last 12 months FCF margin is -151%. |
| What is the current EV/FCF multiple of Abionyx Pharma? | Current FCF multiple of Abionyx Pharma is -5.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
